THE SAFETY OF EXCIPIENTS AS A KEY FACTOR IN SUCCESSFUL DRUG DEVELOPMENT
DOI:
https://doi.org/10.22159/ijap.2025v17i4.52587Keywords:
Excipients, Dosage forms, Excipient dosage, Excipient safety, Biological targets of excipients, Electronic databasesAbstract
Until recently, the safety of excipients had not received much attention, as they were considered pharmacologically indifferent and were included in medicinal products solely to facilitate production or to enhance ease of use. In recent years, excipients have come under greater scrutiny regarding their potential adverse effects on the body, which may have implications for patient safety during routine and long-term use. This article addresses certain aspects of the regulatory framework for excipients in the United States as well as in the countries of the European and Eurasian Unions. Various sources of information on the physicochemical and biological properties of pharmaceutical excipients are examined, along with examples of adverse effects associated with several widely used excipients. Descriptions of electronic databases containing information on excipients in the context of their application are provided, considering dosage, route of administration, dosage forms, and potential biological targets. A comparison of these databases is also provided.
References
Sheskey PJ, Hancock BC, Moss GP, Goldfarb DJ, editors. Handbook of pharmaceutical excipients. 9th ed. London: Pharmaceutical Press; 2020. p. 1400.
Eurasian Economic Commission. Place of publication unknown; 2018 Jul 20. Available from: https://docs.eurasianeconomiccommission.eaeunion.org/upload/iblock/48f/168lf54epet2i8rd7bjkxdr5ousxsx2l/cncd_20072018_doc.pdf. [Last accessed on 10 Sep 2024].
Mannion R. Complex generics and regulatory challenges. Silver spring (MD): center for research on complex generics; 2022 Dec 6. Available from: https://www.complexgenerics.org/wp-content/uploads/crcg/prsnt-mannion20221206-crcg-62.pdf. [Last accessed on 18 Sep 2024].
Radhika G, Sharvani A, Hemanth Eswar Teja Y, Prasanthi D. Comprehensive regulations for drug and cosmetics in European Union. Int J Pharm Pharm Sci. 2025;17(2):26-32.
Goupil R, Tsuyuki RT, Santesso N, Terenzi KA, Habert J, Cheng G. Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care. CMAJ. 2025;197(20):E549-64. doi: 10.1503/cmaj.241770, PMID 40419299.
Pharmacentral. Place of publication unknown: Pharmacentral. Pharmaceutical excipients safety: it’s not only about toxicology. Available from: https://pharmacentral.com/learning-hub/technical-guides/pharmaceutical-excipients-safety-its-not-only-about-toxicology. [Last accessed on 01 Oct 2024].
Europe IP. Brussels (BE): Available from: https://www.ipec-europe.orginternationalpharmaceuticalexcipientscouncileurope. [Last accessed on 18 Sep 2024].
International Pharmaceutical Excipients Council. IPEC excipient stability guide for pharmaceutical excipients. In: Brussels, Belgium: International Pharmaceutical Excipients Council; 2022. Available from: https://www.ipec-europe.org/guidelines.html?y=2022. [Last accessed on 08 Sep 2024].
International Pharmaceutical Excipients Council. The IPEC excipient information package sustainability chapter. In: Brussels, Belgium: International Pharmaceutical Excipients Council; 2023. Available from: https://www.ipec-europe.org/guidelines.html. [Last accessed on 08 Sep 2024].
International Pharmaceutical Excipients Council. IPEC significant change guide. In: Brussels, Belgium: International Pharmaceutical Excipients Council; 2023. Available from: https://www.ipec-europe.org/guidelines.html.
International Pharmaceutical Excipients Council. The IPEC good distribution practices audit guide for pharmaceutical excipients. In: Brussels, Belgium: International Pharmaceutical Excipients Council; 2021. Available from: https://www.ipec-europe.org/guidelines.html.
International Pharmaceutical Excipients Council. The IPEC certificate of analysis guide for pharmaceutical excipients. In: Brussels, Belgium: International Pharmaceutical Excipients Council; 2024. Available from: https://www.ipec-europe.org/guidelines.html. [Last accessed on 08 Sep 2024].
International Pharmaceutical Excipients Council. The IPEC qualification of excipients for use in pharmaceuticals. In: Brussels, Belgium: International Pharmaceutical Excipients Council; 2020. Available from: https://www.ipec-europe.org/guidelines.html. [Last accessed 08 Sep 2024].
International Pharmaceutical Excipients Council. IPEC-PQG good manufacturing practices guide. In: Brussels, Belgium: International Pharmaceutical Excipients Council; 2022. Available from: https://www.ipec-europe.org/guidelines.html. [Last accessed on 08 Sep 2024].
MedlinePlus. Phosphorus: MedlinePlus Medical Encyclopedia. Bethesda: United States National Library of Medicine. Available from: https://medlineplus.gov/ency/article/00267814.html. [Last accessed on 03 Sep 2024].
Spectrum Chemical Mfg. Corp. Safety data sheet: thimerosal, USP. Gardena: Spectrum Chemical Mfg. Corporation; 2022. Available from: https://www.spectrumchemical.com/msds/th125_aghs.pdf. [Last accessed on 18 Sep 2024].
Conklin L, Hviid A, Orenstein WA, Pollard AJ, Wharton M, Zuber P. Vaccine safety issues at the turn of the 21st century. BMJ Glob Health. 2021 May;6 Suppl 2:e004898. doi: 10.1136/bmjgh-2020-004898, PMID 34011504, PMCID PMC8137241.
Caballero ML, Krantz MS, Quirce S, Phillips EJ, Stone CA Jr. Hidden dangers: recognizing excipients as potential causes of drug and vaccine hypersensitivity reactions. J Allergy Clin Immunol Pract. 2021 Aug;9(8):2968-82. doi: 10.1016/j.jaip.2021.03.002, PMID 33737254, PMCID PMC8355062.
Sanofi pasteur. Fluson® quadrivalent. Swiftwater (pa): sanofi pasteur; 2021. Influenza virus vaccine quadrivalent types a and b (split virion). Product [monograph]. Available from: https://pdf.hres.ca/dpd_pm/00062890.pdf. [Last accessed on 18 Sep 2024].
Yorifuji T, Kado Y, Diez MH, Kishikawa T, Sanada S. Neurological and neurocognitive functions from intrauterine methylmercury exposure. Arch Environ Occup Health. 2016 May 3;71(3):170-7. doi: 10.1080/19338244.2015.1080153, PMID 26267674.
Masten SA. Butylparaben: review of toxicological literature. NC: National institute of environmental health sciences; 2005. Available from: https://ntp.niehs.nih.gov/ntp/htdocs/chem_background/exsumpdf/butylparaben_508.pdf. [Last accessed 28 on May 2025].
Amadasi A, Mozzarelli A, Meda C, Maggi A, Cozzini P. Identification of xenoestrogens in food additives by an integrated in silico and in vitro approach. Chem Res Toxicol. 2009 Jan;22(1):52-63. doi: 10.1021/tx800048m, PMID 19063592, PMCID PMC2758355.
World Health Organization. Geneva [CH]. WHO; 2022 Oct 5. Medical product alert N° 6/2022: substandard (contaminated) paediatric medicines. Available from: https://www.who.int/news/item/05-10-2022-medical-product-alert-n-6-2022-substandard-(contaminated)-paediatric-medicines. [Last accessed on 04 Sep 2024].
Gupta A, Kumar J, Verma S, Singh H. Application of quality by design approach for the optimization of orodispersible film formulation. Asian J Pharm Clin Res. 2018;11(14):8-11. doi: 10.22159/ajpcr.2018.v11s2.28508.
Krantz MS, Liu Y, Phillips EJ, Stone CA JR. Anaphylaxis to pegylated liposomal echocardiogram contrast in a patient with IgE-mediated macrogol allergy. J Allergy Clin Immunol Pract. 2020 Apr;8(4):1416-1419.e3. doi: 10.1016/j.jaip.2019.12.041, PMID 31954852, PMCID PMC7263401.
Ionova Y, Wilson L. Biologic excipients: importance of clinical awareness of inactive ingredients. PLOS One. 2020 Jun 25;15(6):e0235076. doi: 10.1371/journal.pone.0235076, PMID 32584876, PMCID PMC7316246.
Pantin C, Letellez J, Calzas J, Mohedano E. Indirect identification of hypersensitivity reaction to etoposide mediated by polysorbate 80. Farm Hosp. 2018 Jan 1;42(1):27-8. doi: 10.7399/fh.10882, PMID 29306312.
Perino E, Freymond N, Devouassoux G, Nicolas JF, Berard F. Xolair induced recurrent anaphylaxis through sensitization to the excipient polysorbate. Ann Allergy Asthma Immunol. 2018 Jun;120(6):664-6. doi: 10.1016/j.anai.2018.02.018, PMID 29481891.
Pottel J, Armstrong D, Zou L, Fekete A, Huang XP, Torosyan H. The activities of drug inactive ingredients on biological targets. Science. 2020 Jul 24;369(6502):403-13. doi: 10.1126/science.aaz9906, PMID 32703874, PMCID PMC7960226.
Bibera MA, Lo KM, Steele A. Potential cross reactivity of polysorbate 80 and cremophor: a case report. J Oncol Pharm Pract. 2020 Jul;26(5):1279-81. doi: 10.1177/1078155219896848, PMID 31955702.
Meduniver. Cremophor EL poisoning and its side effects. Available from: https://meduniver/medical/toksikologia/otravlenie_kremoforom.html. [Last accessed on 08 Sep 2024].
Brockow K, Bauerdorf F, Kugler C, Darsow U, Biedermann T. ‘Idiopathic’ anaphylaxis caused by carboxymethylcellulose in ice cream. J Allergy Clin Immunol Pract. 2021 Jan;9(1):555-557.e1. doi: 10.1016/j.jaip.2020.10.051, PMID 33181345.
International Programme on Chemical Safety. Geneva (CH). World Health Organization; PIM 443: methylmercury. Available from: https://www.inchem.org/documents/pims/chemical/pim443.htm#sectiontitle:9.1%20%20acute%20poisoning. [Last accessed on 18 Sep 2024].
Farooque S, Kenny M, Marshall SD. Anaphylaxis to intravenous gelatine based solutions: a case series examining clinical features and severity. Anaesthesia. 2019 Feb;74(2):174-9. doi: 10.1111/anae.14497, PMID 30520028.
Abdul Bari M. The excipients between effects and the side effects. Med Care Res Rev. 2019 May;2(5):178.
Nemes D, Kovacs R, Nagy F, Mezo M, Poczok N, Ujhelyi Z. Interaction between different pharmaceutical excipients in liquid dosage forms assessment of cytotoxicity and antimicrobial activity. Molecules. 2018 Jul 23;23(7):1827. doi: 10.3390/molecules23071827, PMID 30041418, PMCID PMC6100184.
European Medicines Agency. Annex to the European commission guideline on excipients in the labelling and package leaflet of medicinal products for human use. Available from: https://www.ema.europa.eu/en/annex-europeancommission-guideline-excipients-labelling-package-leaflet-medicinal-products-human-use. [Last accessed on 04 Feb 2025].
Kriegel C, Festag M, Kishore RS, Roethlisberger D, Schmitt G. Pediatric safety of polysorbates in drug formulations. Children (Basel). 2019 Dec 20;7(1):1. doi: 10.3390/children7010001, PMID 31877624, PMCID PMC7022221.
Rouaz K, Chiclana Rodriguez B, Nardi Ricart A, Sune Pou M, Mercade Frutos D, Sune Negre JM. Excipients in the paediatric population: a review. Pharmaceutics. 2021 Mar 13;13(3):387. doi: 10.3390/pharmaceutics13030387, PMID 33805830, PMCID PMC8000418.
Saito J, Agrawal A, Patravale V, Pandya A, Orubu S, Zhao M. The current states challenges ongoing efforts and future perspectives of pharmaceutical excipients in pediatric patients in each country and region. Children (Basel). 2022 Mar 23;9(4):453. doi: 10.3390/children9040453, PMID 35455497, PMCID PMC9026161.
FDA. Pediatric research equity act (PREA). In: Silver Spring (MD): United States Food and Drug Administration; Available from: https://www.fda.gov/drugs/development-resources/pediatric-research-equity-act-prea. [Last accessed on 20 Jan 2025].
European Medicines Agency. Paediatric regulation. In: Amsterdam: EMA; Available from: https://www.ema.europa.eu/en/human-regulatory-overview/paediatric-medicines-overview/paediatric-regulation.
Sujith T, Chakradhar T, Marpaka S, Sowmini K. Aspects of utilization and limitations of artificial intelligence in drug safety. Asian J Pharm Clin Res. 2021;14(8):34-9. doi: 10.22159/ajpcr.2021.v14i8.41979.
Wang Z, Liang L, Yin Z, Lin J. Improving chemical similarity ensemble approach in target prediction. J Cheminform. 2016 Apr 23;8:20. doi: 10.1186/s13321-016-0130-x, PMID 27110288, PMCID PMC4842302.
Nash A. Similarity ensemble approach finding targets (receptor proteins) for small molecules; 2019. Available from: https://distributedscience.wordpress.com.similarity-ensemble-approach-finding-targets-receptor-proteins-for-small-molecules. [Last accessed on 18 Sep 2024].
US Food and Drug Administration. Highlights of prescribing information: doxorubicin hydrochloride liposome injection for intravenous use. Food and Drug Administration; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/050718Orig1s060lbl.pdf. [Last accessed on 10 Sep 2024].
US Food and Drug Administration. Guidance for industry: nonclinical studies for the safety evaluation of pharmaceutical excipients. Silver Spring, (MD): FDA; 2005 May. Available from: https://www.fda.gov/media/72260/download.
US Food and Drug Administration. Inactive ingredients database download. In: Silver Spring, (MD): FDA; Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredients-database-download. [Last accessed on 18 Sep 2024].
Salunke S, Brandys B, Giacoia G, Tuleu C. The step (safety and toxicity of excipients for paediatrics) database: part-2 the pilot version. Int J Pharm. 2013;457(1):310-22. doi: 10.1016/j.ijpharm.2013.09.013, PMID 24070789.
European Paediatric Formulation Initiative (EuPFI) STEP Database. London UK: University College London. Available from: https://step-db.ucl.ac.uk/eupfi/appDirectLink.do?appFlag=login. [Last accessed on 10 Sep 2024].
Zhang C, Mou M, Zhou Y, Zhang W, Lian X, Shi S. Biological activities of drug inactive ingredients. Brief Bioinform. 2022 Sep 20;23(5):bbac160. doi: 10.1093/bib/bbac160, PMID 35524477.
ACDINA. Hangzhou (CN): Innovative Drug Research and Bioinformatics Group. Zhejiang University. Available from: https://acdina.idrblab.net/ttd. [Last accessed on 10 Sep 2024].
UniProt Consortium. UniProt: the universal protein knowledgebase in 2023. Nucleic Acids Res. 2023 Jan 6;51(D1):D523-31. doi: 10.1093/nar/gkac1052, PMID 36408920, PMCID PMC9825514.
PubChem. Bethesda: Available from: https://pubchem.ncbi.nlm.nih.gov/. [Last accessed on 18 Sep 2024].
Gene NC. In: Bethesda: National Center for Biotechnology Information, United States National Library of Medicine; Available from: https://www.ncbi.nlm.nih.gov/gene/. [Last accessed 18 Sep 2024].
Gene NC. In: Bethesda: National Center for Biotechnology Information, United States National Library of Medicine; Available from: https://www.ncbi.nlm.nih.gov/gene/. [Last accessed 18 Sep 2024].
Published
How to Cite
Issue
Section
Copyright (c) 2025 NATALIA DEMINA, ELENA BAKHRUSHINA, MARIA ANUROVA, SALMA ABUELEZ, IRINA ZUBAREVA, IVAN KRASNYK
This work is licensed under a Creative Commons Attribution 4.0 International License.
